ACP
AGIO icon

Acuta Capital Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Acuta Capital Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40,000
Closed -$2.29M – 63
2017
Q4 		$2.29M Buy
+40,000
New +$2.52M 0.43% 32

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Acuta Capital Partners's AGIO Position: Q3 2024 in Review

Acuta Capital Partners sold out of Agios Pharmaceuticals (AGIO) in Q3 2024, closing a stake of 78,700 shares — an estimated $3.39M sold.

Acuta Capital Partners first reported a position in AGIO in Q3 2016 and held it in 3 quarters. The position peaked at $3.39M in Q2 2024. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2024.

  • Acuta Capital Partners reported no remaining Agios Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 78,700 Agios Pharmaceuticals shares in Q3 2024, an estimated $3.39M.
  • Acuta Capital Partners first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Acuta Capital Partners's Agios Pharmaceuticals position peaked at $3.39M in Q2 2024.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.